Discovery of 2-(4-Pyridin-2-ylpiperazin-1-ylmethyl)-1 H -benzimidazole (ABT-724), a Dopaminergic Agent with a Novel Mode of Action for the Potential Treatment of Erectile Dysfunction

Citations Over TimeTop 10% of 2004 papers

Abstract

A new class of agents with potential utility for the treatment of erectile dysfunction has been discovered, guided by the hypothesis that selective D4 agonists are erectogenic but devoid of the side effects typically associated with dopaminergic agents. The lead agent 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (1, ABT-724) was discovered by optimization of a series of benzimidazole arylpiperazines. This highly selective D4 agonist was found to be very potent and efficacious in vivo, eliciting penile erections in rats at a dose of 0.03 micromol/kg, with a positive response rate of 77% erectile incidence. Even at high doses, it was devoid of side effects in animal models of central nervous system behaviors, emesis, or nausea. The structure-activity relationship of the parent benzimidazole series leading to 1 is described, with the detailed in vitro and in vivo profiles described. Distinctive structural features were discovered that are associated with D4 selective agonism in this series of analogues.

Related Papers

• Synthesis and antimicrobial activity of certain benzimidazole and fused benzimidazole derivatives(2010)
• Microwave Synthesis,Characteristics and Antibacterial Activities of Benzimidazole Derivatives(2006)
• → Syntheses of Some Benzimidazoles from N-Arylamidines(1966)5 cited
• → Synthesis of substituted 4H-imidazo[5,1-B]benzimidazole VII. Derivatives of 3-phenyl-4-methylimidazo[5,1-b]benzimidazole and 3,4-dimethylimidazo[5,1-b]benzimidazole(1972)2 cited
• → Benzimidazole(2003)